tate28 Jun 2014 10:50
It can be risky 'catching falling knives', but in the case of Tate & Lyle (TATE), a recent share price slump provides an attractive entry point to its long-term growth story. The shares have fallen 15 per cent since the beginning of the year and are now lingering at an unjustifiably low rating compared with their global peers. We think this offers investors a unique, albeit contrarian opportunity buy into a well-run company with a healthy balance sheet, that not only promises solid long-term growth at a massive markdown, but serves up a sweet 4 per cent dividend yield as well.
Since the sale of its sugar business in 2010, Tate has been focused on high-tech food ingredients and industrial goods, producing things such as corn syrup, ethanol, specialised starches, texturants and sweeteners. Its two divisions - bulk and speciality food - are highly profitable, but it’s the latter which offers the most exciting potential for growth and is benefiting from a great deal of investment.
Speciality food (SFI) accounts for 31 per cent of Tate's group sales, but higher margins mean it delivers 55 per cent of operating profit, so it's a vital business. It’s growing too, as industry trends are working in its favour: food producers - Tate's clients - are increasingly using products that address calorie and weight management, heart and digestive health, alongside additives that extend shelf-life and enhance texture and taste. Tate can cater to all of this through its range of sweeteners, both artificial and natural, heart-friendly fibres, starches and low-sodium salt. The innovation pipeline is replete with 35 products, with several to be introduced in the next 12 to 18 months.
Emerging markets are a particularly strong growth area, representing one-fifth of SFI sales. Last year Asia Pacific and Latin America produced double-digit volume growth. Acquisitions, though small, are promising too and give Tate a toe-hold in important geographic regions. For example, recently-acquired Chinese polydextrose fibre company Winway offers a springboard from which to expand across Asia. And Swedish oat fibre start-up, Biovelop, has isolated an oat-based fibre proven to reduce cholesterol and control blood-sugar levels. Having snapped it up, Tate plans to more than treble the size of the business. This is all part of a wider £100m investment into the SFI division, which will increase capacity, promote new products and lead to cost savings.
But all is not rosy in SFI. The division suffered a serious setback in February when a significant overhang of generic Chinese sucralose stock sent prices plummeting, just as Tate was renewing several multi-year contracts for its Splenda sucralose, which accounts about a fifth of the division's revenue. As a result, profits are expected to dip slightly this year. The good news, though, is that half of Splenda sales goes into food where formulation technology and application support is necessary - something w